Regen BioPharma Inc (RGBP)

[Canadian Trader]

RGBP obtained the following IP for Ebola:

IP DESCRIPTION: Immune Modulation by TLR Activation for Treatment of Filovirus Infections Including Ebola
PATENT NUMBER: 62085636
APPLICATION DATE: 12/15/2014
PRIORITY DATE: 11/30/2014

http://regenbiopharma.com/intellectual-property.html

So they've made some progress in this area, but if I had to guess it's obviously not the frontrunner of their product pipeline. Perhaps the new lab and new hires will assist with pursuing this further.

$ RGBP $.